Get started
Author

Thomas Eckmann

OPREVENT2: Design of a multi-institutional intervention for obesity control and prevention for American Indian adults
2017 · Joel Gittelsohn, Brittany Jock, et al. · BMC Public Health · 42
PDF
A National Survey of Burnout and Depression Among Fellows Training in Pulmonary and Critical Care Medicine
2020 · Michelle Sharp, Kristin M. Burkart, et al. · CHEST Journal · 40
Factors Associated with Home Meal Preparation and Fast-Food Sources Use among Low-Income Urban African American Adults
2017 · Mariana T. Garcia, Priscila M. Sato, et al. · Ecology of Food and Nutrition · 26
Effectiveness of a Home- and School-Based Asthma Educational Program for Head Start Children With Asthma
2020 · Michelle N. Eakin, Sandra Zaeh, et al. · Archives of Pediatrics and Adolescent Medicine · 25
PDF
Development and Implementation: B’More Healthy Communities for Kid’s Store and Wholesaler Intervention
2017 · Teresa Schwendler, Cara Shipley, et al. · Health Promotion Practice · 23
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America
2024 · Bruce Strober, Yichen Zhong, et al. · Journal of Psoriasis and Psoriatic Arthritis · 15
PDF
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
2023 · Bruce Strober, Laura Ferris, et al. · Journal of the American Academy of Dermatology · 13
Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry
2023 · Robert R. McLean, Adam P. Sima, et al. · Dermatology and Therapy · 10
PDF
Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification
2025 · Bruce Strober, Manish Patel, et al. · Dermatology and Therapy · 7
PDF
Similar response to biologic therapy across racial and ethnic groups among patients with psoriasis enrolled in the CorEvitas Psoriasis Registry
2022 · Clinton W. Enos, Julie Z. Yi, et al. · Journal of the American Academy of Dermatology · 7
PDF
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
2024 · Mark Lebwohl, Bruce Strober, et al. · Drugs - Real World Outcomes · 5
Association Between Participant Contact Attempts and Reports of Being Bothered in a National, Longitudinal Cohort Study of ARDS Survivors
2020 · Michelle N. Eakin, Thomas Eckmann, et al. · CHEST Journal · 5
Increasing Physical Activity in American Indian Adults: Preliminary Results from a Multi‐institutional Obesity Prevention Program
2016 · Leslie Redmond, Thomas Eckmann, et al. · The FASEB Journal · 2
Racial/ethnic differences in biologic treatment patterns among patients with psoriasis: A prospective analysis of patients in the CorEvitas Psoriasis Registry
2024 · Clinton W. Enos, Julie Z. Yi, et al. · Journal of the American Academy of Dermatology · 1
PDF
Impact of atopic dermatitis lesion locations and extent on patient burden: A real‐world study
2024 · Eric Simpson, Peter Lio, et al. · JEADV Clinical Practice · 1
PDF
34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
2022 · April W. Armstrong, Laura K. Ferris, et al. · Journal of the American Academy of Dermatology · 1
Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry
2026 · Mark G. Lebwohl, Ranga Gogineni, et al. · Dermatology and Therapy
PDF
Real-world Tildrakizumab Effectiveness and Drug Survival: A Cohort Study in the PPD CorEvitas Psoriasis Registry
2026 · Jerry Bagel, Ranga Gogineni, et al. · Dermatology and Therapy
PDF
61353 Real-World Skin Clearance and Quality of Life With Risankizumab in Patients Eligible for Systemic Therapy per International Psoriasis Council Criteria
2025 · Bruce Strober, Manish Patel, et al. · Journal of the American Academy of Dermatology
62638 Treatment patterns, drug survival, and effectiveness of tildrakizumab in biologic-naïve and biologic-experienced patients in the CorEvitas Psoriasis Registry
2025 · Jerry Bagel, Ranga Gogineni, et al. · Journal of the American Academy of Dermatology
62641 Treatment patterns, drug survival, and effectiveness of tildrakizumab among patients with prior interleukin-17 experience in the CorEvitas Psoriasis Registry
2025 · Mark G. Lebwohl, Ranga Gogineni, et al. · Journal of the American Academy of Dermatology
62300 Long-Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response in Patients with Moderate to Severe Psoriasis Treated with Risankizumab: 3 Year Results from the CorEvitas Psoriasis Registry
2025 · April W. Armstrong, Laura K. Ferris, et al. · Journal of the American Academy of Dermatology
62631 Characteristics and treatment outcomes of patients with prior apremilast experience treated with tildrakizumab in the CorEvitas Psoriasis Registry
2025 · Jerry Bagel, Ranga Gogineni, et al. · Journal of the American Academy of Dermatology
Long-Term Effectiveness of Guselkumab vs. Other Biologic Therapies Among Plaque Psoriasis Patients in the CorEvitas Psoriasis Registry
2025 · Bruce Strober, April Armstrong, et al. · SKIN The Journal of Cutaneous Medicine
Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%)
2024 · Bruce Strober, Manish Patel, et al. · SKIN The Journal of Cutaneous Medicine
Works count: 36
Citation count: 223
H-index: 8
I10-index: 8
Year
Topic
Type